Zacks
Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
📉
AI Sentiment
Negative
2/10
- Home
- IVVD
IVVD
Invivyd Inc.
as of 02-20-2026 4:00pm EST
$1.55
$0.06
-3.73%
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
| Founded: | 2020 | Country: | United States |
| Employees: | 100 | City: | NEW HAVEN |
| Market Cap: | 437.1M | IPO Year: | 2021 |
| Target Price: | $8.75 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.30 | EPS Growth: | 20.99 |
| 52 Week Low/High: | $0.46 - $3.07 | Next Earning Date: | 04-11-2026 |
| Revenue: | $25,384,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 107.86% | Revenue Growth (next year): | 146.53% |
| P/E Ratio: | -5.17 | Index: | N/A |
| Free Cash Flow: | -170631000.0 | FCF Growth: | N/A |
AI-Powered IVVD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 74.19%
74.19%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Invivyd Inc. (IVVD)
Green Julie
Sell
Chief Human Resources Officer
IVVD Feb 18, 2026
Avg Cost/Share
$1.58
Shares
20,964
Total Value
$33,077.00
Owned After
107,717
SEC Form 4
Andersen Jill
Sell
Chief Legal Officer, Secretary
IVVD Feb 18, 2026
Avg Cost/Share
$1.58
Shares
34,939
Total Value
$55,126.75
Owned After
181,736
SEC Form 4
Duke William E.
Sell
Chief Financial Officer
IVVD Feb 18, 2026
Avg Cost/Share
$1.58
Shares
20,964
Total Value
$33,077.00
Owned After
107,717
SEC Form 4
Lee Timothy Edward
Sell
Chief Commercial Officer
IVVD Feb 18, 2026
Avg Cost/Share
$1.58
Shares
20,964
Total Value
$33,077.00
Owned After
117,717
SEC Form 4
Allen Robert D. III
Sell
Chief Scientific Officer
IVVD Feb 18, 2026
Avg Cost/Share
$1.58
Shares
19,392
Total Value
$30,596.70
Owned After
114,487
SEC Form 4
Green Julie
Sell
Chief Human Resources Officer
IVVD Feb 17, 2026
Avg Cost/Share
$1.54
Shares
19,663
Total Value
$30,273.15
Owned After
107,717
SEC Form 4
Andersen Jill
Sell
Chief Legal Officer, Secretary
IVVD Feb 17, 2026
Avg Cost/Share
$1.54
Shares
32,771
Total Value
$50,454.23
Owned After
181,736
SEC Form 4
Duke William E.
Sell
Chief Financial Officer
IVVD Feb 17, 2026
Avg Cost/Share
$1.54
Shares
19,663
Total Value
$30,273.15
Owned After
107,717
SEC Form 4
Lee Timothy Edward
Sell
Chief Commercial Officer
IVVD Feb 17, 2026
Avg Cost/Share
$1.54
Shares
19,663
Total Value
$30,273.15
Owned After
117,717
SEC Form 4
Allen Robert D. III
Sell
Chief Scientific Officer
IVVD Feb 17, 2026
Avg Cost/Share
$1.54
Shares
18,189
Total Value
$28,003.78
Owned After
114,487
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Green Julie | IVVD | Chief Human Resources Officer | Feb 18, 2026 | Sell | $1.58 | 20,964 | $33,077.00 | 107,717 | |
| Andersen Jill | IVVD | Chief Legal Officer, Secretary | Feb 18, 2026 | Sell | $1.58 | 34,939 | $55,126.75 | 181,736 | |
| Duke William E. | IVVD | Chief Financial Officer | Feb 18, 2026 | Sell | $1.58 | 20,964 | $33,077.00 | 107,717 | |
| Lee Timothy Edward | IVVD | Chief Commercial Officer | Feb 18, 2026 | Sell | $1.58 | 20,964 | $33,077.00 | 117,717 | |
| Allen Robert D. III | IVVD | Chief Scientific Officer | Feb 18, 2026 | Sell | $1.58 | 19,392 | $30,596.70 | 114,487 | |
| Green Julie | IVVD | Chief Human Resources Officer | Feb 17, 2026 | Sell | $1.54 | 19,663 | $30,273.15 | 107,717 | |
| Andersen Jill | IVVD | Chief Legal Officer, Secretary | Feb 17, 2026 | Sell | $1.54 | 32,771 | $50,454.23 | 181,736 | |
| Duke William E. | IVVD | Chief Financial Officer | Feb 17, 2026 | Sell | $1.54 | 19,663 | $30,273.15 | 107,717 | |
| Lee Timothy Edward | IVVD | Chief Commercial Officer | Feb 17, 2026 | Sell | $1.54 | 19,663 | $30,273.15 | 117,717 | |
| Allen Robert D. III | IVVD | Chief Scientific Officer | Feb 17, 2026 | Sell | $1.54 | 18,189 | $28,003.78 | 114,487 |
Latest Invivyd Inc. News
IVVD Breaking Stock News: Dive into IVVD Ticker-Specific Updates for Smart Investing
MT Newswires
UBS Lifts Price Target on Ross Stores to $199 From $181, Maintains Neutral Rating
📊
AI Sentiment
Positive
7/10
MT Newswires
UBS Adjusts Price Target on eBay to $93 From $95, Maintains Neutral Rating
âž–
AI Sentiment
Neutral
5/10
GuruFocus.com
Engcon AB (ENGCF) Q4 2025 Earnings Call Highlights: Strong Sales Growth Amid Margin Pressures
📊
AI Sentiment
Positive
7/10
Compare IVVD vs Leading Stocks
See how IVVD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IVVD Invivyd Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.